Generic Name and Formulations:
Mesna 400mg; tabs.
Indications for MESNEX:
Prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.
See literature. IV Schedule: Give as IV bolus injection in a dosage equal to 20% of the ifosfamide dose at the time of ifosfamide administration and 4 and 8 hours after each dose of ifosfamide; total daily dose is 60% the ifosfamide dose. IV and oral dosing: Give as IV bolus injection in a dosage equal to 20% of the ifosfamide dose at the time of ifosfamide administration, followed by the tablets given orally in a dosage equal to 40% of the ifosfamide dose 2 and 6 hours after each dose of ifosfamide; total daily dose is 100% of the ifosfamide dose. Repeat schedule on each day ifosfamide is given. If vomiting occurs within 2hrs of oral mesna, repeat dose or give IV mesna.
Hypersensitivity to thiol compounds.
Monitor morning specimen of urine for the presence of hematuria each day prior to ifosfamide therapy; consider dose reduction or discontinue if hematuria occurs. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.
GI upset, fever, anorexia, flatulence, constipation, rhinitis, rigors, back pain, rash, conjunctivitis, arthralgia, headache, inj site reactions, flushing, dizziness, pharyngitis, hyperaesthesia, flu-like symptoms, coughing; hypersensitivity reactions.
Patients taking mesna should drink at least a quart of liquid a day.
Tabs—10; Multidose vials—1, 10
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline